Background: Since 2011 public concerns about Human Papillomavirus (HPV) vaccination safety and efficacy arose in France. We explored the relevance of using vaccines reimbursement data to assess the impact of those public concerns on vaccination coverage.
Methods: We used the Permanent Sample of Beneficiaries which was, at the time of the study, a representative sample of 1/97(th) health insurance beneficiaries of the main Social Security scheme, the General Health Insurance Scheme, covering approximately 77 % of the French resident population. We estimated HPV vaccination coverage among girls born between 1995 and 1999 at their 15(th), 16(th) and 17(th) birthday.
Results: The coverage for complete vaccination among 16 years old girls decreased from 26.5 % in the first semester of 2011 to 18.6 % in the first semester of 2014.
Conclusions: HPV vaccination coverage was already low in 2011 and continued to decrease thereafter. Vaccines reimbursement data allowed us to reactively monitor the impact of the controversy on vaccination coverage and design counteracting measures.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4676816 | PMC |
http://dx.doi.org/10.1186/s12889-015-2575-7 | DOI Listing |
Cureus
December 2024
Social Sciences School, Hellenic Open University, Athens, GRC.
The COVID-19 pandemic posed a major public health challenge during its early stages, and vaccine distribution played a critical role in the initial response. This cohort study examines the socioeconomic and demographic factors influencing attitudes towards COVID-19 vaccination in Western Attica, Greece. The data was collected in two phases: In the first phase (December 2021-January 2022), 269 people who had initially refused the vaccination were surveyed.
View Article and Find Full Text PDFInfect Dis Model
June 2025
Department of Statistics, IME, Federal University of Bahia, Salvador, BA, Brazil.
This paper presents an investigation into the spatio-temporal dynamics of Severe Acute Respiratory Syndrome (SARS) across the diverse health regions of Brazil from 2016 to 2024. Leveraging extensive datasets that include SARS cases, climate data, hospitalization records, and COVID-19 vaccination information, our study employs a Bayesian spatio-temporal generalized linear model to capture the intricate dependencies inherent in the dataset. The analysis reveals significant variations in the incidence of SARS cases over time, particularly during and between the distinct eras of pre-COVID-19, during, and post-COVID-19.
View Article and Find Full Text PDFLancet Reg Health Eur
March 2025
Department of Cervical Cancer Screening, Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia.
Background: HPV vaccination is most efficacious in preventing cervical cancer and its precursors when administered during preadolescence. Because in Slovenia women are invited for cytology screening from age 20, women targeted for preadolescent HPV vaccination have been screening-eligible since 2018. We aim to assess the impact of preadolescent HPV vaccination programme on cytology screening performance and CIN2+ incidence.
View Article and Find Full Text PDFJ Epidemiol Glob Health
January 2025
Department of Eco-Epidemiology, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Background: Since its resurgence in 2017, Yellow fever (YF) outbreaks have continued to occur in Nigeria despite routine immunization and the implementation of several reactive mass vaccinations. Nigeria, Africa's most populous endemic country, is considered a high-priority country for implementing the End Yellow fever Epidemics strategy.
Methods: This retrospective analysis described the epidemiological profile, trends, and factors associated with Yellow fever viral positivity in Nigeria.
Zhonghua Yu Fang Yi Xue Za Zhi
January 2025
National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing100050, China.
Mass vaccination represents a highly effective strategy for accelerating disease control while simultaneously reducing incidence and mortality rates. By developing comprehensive plans and standards for mass vaccination, it is feasible to optimize resource allocation and swiftly enhance vaccination coverage, thereby preventing, controlling, or interrupting outbreaks or epidemics of specific infectious diseases. To standardize the mass vaccination process and establish a population immunity barrier in an orderly, efficient, and safe manner, a panel of experts was convened to develop the Recommendations on Mass Vaccination.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!